Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pharmather Hldgs Ltd (PHRRF)

Pharmather Hldgs Ltd (PHRRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and...

PHRM.CN : 0.145 (+3.57%)
PHRRF : 0.1068 (+1.62%)
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.145 (+3.57%)
PHRRF : 0.1068 (+1.62%)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.145 (+3.57%)
PHRRF : 0.1068 (+1.62%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1068 (+1.62%)
PHRM.CN : 0.145 (+3.57%)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.145 (+3.57%)
PHRRF : 0.1068 (+1.62%)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1068 (+1.62%)
PHRM.CN : 0.145 (+3.57%)
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Third FDA orphan drug designation for ketamine granted to PharmaTher...

PHRRF : 0.1068 (+1.62%)
PHRM.CN : 0.145 (+3.57%)
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the...

PHRRF : 0.1068 (+1.62%)
PHRM.CN : 0.145 (+3.57%)
PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022...

PHRM.CN : 0.145 (+3.57%)
PHRRF : 0.1068 (+1.62%)
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage...

PHRRF : 0.1068 (+1.62%)
PHRM.CN : 0.145 (+3.57%)

Barchart Exclusives

Elon Musk Just Gave Investors Another Reason to Buy Berkshire Hathaway Stock 
Tesla (TSLA) was just passed by BYD (BYDDY) as the world’s largest producer of electric vehicles (EV). Berkshire Hathaway (BRK.B) is one of BYD’s largest shareholders. BYD is another reason to own Berkshire stock. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar